TY - JOUR
T1 - IL-8 as a urinary biomarker for the detection of bladder cancer
AU - Urquidi, Virginia
AU - Chang, Myron
AU - Dai, Yunfeng
AU - Kim, Jeongsoon
AU - Wolfson, Edward D.
AU - Goodison, Steve
AU - Rosser, Charles J.
N1 - Funding Information:
The authors are grateful to the 127 subjects who participated in this clinical study. This work was supported by research grants from Flight Attendant Medical Research Institute (CJR), Florida Department of Health James and Esther King Team Science Award 10KT-01 (CJR), and National Cancer Institute RO1 CA116161 (SG).
PY - 2012
Y1 - 2012
N2 - Background: Current urine-based assays for bladder cancer (BCa) diagnosis lack accuracy, so the search for improved biomarkers continues. Through genomic and proteomic profiling of urine, we have identified a panel of biomarkers associated with the presence of BCa. In this study, we evaluated the utility of three of these biomarkers, interleukin 8 (IL-8), Matrix metallopeptidase 9 (MMP-9) and Syndecan in the diagnosis of BCa through urinalysis. Methods. Voided urines from 127 subjects, cancer subjects (n=64), non-cancer subjects (n=63) were analyzed. The protein concentrations of IL-8, MMP-9, and Syndecan were assessed by enzyme-linked immunosorbent assay (ELISA). Data were also compared to a commercial ELISA-based BCa detection assay (BTA-Trak) and urinary cytology. We used the area under the curve of a receiver operating characteristic (AUROC) to compare the performance of each biomarker. Results: Urinary protein concentrations of IL-8, MMP-9 and BTA were significantly elevated in BCa subjects. Of the experimental markers compared to BTA-Trak, IL-8 was the most prominent marker (AUC; 0.79; 95% confidence interval [CI], 0.72-0.86). Multivariate regression analysis revealed that only IL-8 (OR; 1.51; 95% CI, 1.16-1.97, p=0.002) was an independent factor for the detection of BCa. Conclusions: These results suggest that the measurement of IL-8 in voided urinary samples may have utility for urine-based detection of BCa. These findings need to be confirmed in a larger, prospective cohort.
AB - Background: Current urine-based assays for bladder cancer (BCa) diagnosis lack accuracy, so the search for improved biomarkers continues. Through genomic and proteomic profiling of urine, we have identified a panel of biomarkers associated with the presence of BCa. In this study, we evaluated the utility of three of these biomarkers, interleukin 8 (IL-8), Matrix metallopeptidase 9 (MMP-9) and Syndecan in the diagnosis of BCa through urinalysis. Methods. Voided urines from 127 subjects, cancer subjects (n=64), non-cancer subjects (n=63) were analyzed. The protein concentrations of IL-8, MMP-9, and Syndecan were assessed by enzyme-linked immunosorbent assay (ELISA). Data were also compared to a commercial ELISA-based BCa detection assay (BTA-Trak) and urinary cytology. We used the area under the curve of a receiver operating characteristic (AUROC) to compare the performance of each biomarker. Results: Urinary protein concentrations of IL-8, MMP-9 and BTA were significantly elevated in BCa subjects. Of the experimental markers compared to BTA-Trak, IL-8 was the most prominent marker (AUC; 0.79; 95% confidence interval [CI], 0.72-0.86). Multivariate regression analysis revealed that only IL-8 (OR; 1.51; 95% CI, 1.16-1.97, p=0.002) was an independent factor for the detection of BCa. Conclusions: These results suggest that the measurement of IL-8 in voided urinary samples may have utility for urine-based detection of BCa. These findings need to be confirmed in a larger, prospective cohort.
KW - Biomarkers
KW - Bladder cancer
KW - Diagnosis
KW - IL-8
UR - http://www.scopus.com/inward/record.url?scp=84860540588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860540588&partnerID=8YFLogxK
U2 - 10.1186/1471-2490-12-12
DO - 10.1186/1471-2490-12-12
M3 - Article
C2 - 22559832
AN - SCOPUS:84860540588
SN - 1471-2490
VL - 12
JO - BMC Urology
JF - BMC Urology
M1 - 12
ER -